This article is more than 5 years old. Information may no longer be current.
Bridge Medicines, Memorial Sloan Kettering to develop kidney-specific delivery platform for AKI
Click Here to Manage Email Alerts
Bridge Medicines announced it has entered an agreement with Memorial Sloan Kettering to develop a platform designed to deliver drugs specifically to the kidney, with the first disease target to be AKI.
Originated at Memorial Sloan Kettering Cancer Center, Michael R. McDevitt, PhD, ME, and David A. Scheinberg, MD, PhD, chair of the molecular pharmacology program at Memorial Sloan Kettering, director of the Experimental Therapeutics Center and a scientific advisory board member for Bridge Medicines, pioneered the study of functionalized, single-walled carbon nanotubes (fCNT) as platforms for the delivery of biological, radiological and chemical payloads to target tissues, according to a company press release. Most recently, McDevitt and Scheinberg’s work in an animal model of AKI demonstrated successful use of fCNT to deliver of a small interfering ribonucleic acid selectively to the proximal tubule of the kidney.
“I am delighted that Bridge Medicines has the opportunity to work together with Memorial Sloan Kettering on the AKI program: it is innovative and offers the potential to become a breakthrough therapy,” William J. Polvino, MD, CEO of Bridge Medicines, said in the release. “Our team is thrilled to have an opportunity to begin what we hope will be a ground-breaking effort to develop a novel and clinically important therapeutic drug product.”
Reference: